Ornithine phenylacetate: Phase IIa data

Top-line data from 38 patients in an investigator-sponsored, double-blind, Spanish Phase IIa trial showed that 10 g daily IV OCR-002 plus standard of care (SOC) for 5 days led to non-significantly gre...